Selenium supplementation in the treatment of hemodialysis patients

Investigation of the effect of selenium supplementation on gene expression levels associated with insulin, lipid and inflammatory metabolism in diabetic hemodialysis patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170513033941N62

Enrollment

Registered

2019-08-03

Start date

2019-07-09

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis. End stage renal disease

Interventions

Intervention 1: Intervention group: Selenium supplements (Nature, California, USA), 200 µg, daily, for 24 weeks orally. Intervention 2: Control group: Placebo (Barij Essence, Kashan, Iran), daily, for

Eligibility

Sex/Gender

All

Age

45 Years to 75 Years

Inclusion criteria

Inclusion criteria: Diabetic hemodialysis patients aged 45 to 75 years.

Exclusion criteria

Exclusion criteria: Patients taking antioxidant and/or anti-inflammatory supplements within 3 months prior to intervention Patients with infectious diseases Patients with malignant diseases

Design outcomes

Primary

Measure	Time frame
Expressed levels of PPAR-? gene. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: RT-PCR.	—

Secondary

Measure	Time frame
Expressed levels of TNF gene. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of VEGF gene. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of TGF-ß gene. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of IL-1 gene. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of IL-8 gene. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of LDL-ox gene. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: RT-PCR.	—

Measure

Time frame

Expressed levels of TNF gene. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of VEGF gene. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of TGF-ß gene. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of IL-1 gene. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of IL-8 gene. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: RT-PCR.;Expressed levels of LDL-ox gene. Timepoint: At the beginning of the study and after 24 weeks of intervention. Method of measurement: RT-PCR.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac.ir+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026